Evome Medical Technologies Inc.
LNDZF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.55M | 42.86M | 47.50M | 46.44M | 42.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.55M | 42.86M | 47.50M | 46.44M | 42.89M |
| Cost of Revenue | 23.53M | 28.03M | 30.90M | 29.73M | 28.05M |
| Gross Profit | 12.02M | 14.82M | 16.59M | 16.71M | 14.84M |
| SG&A Expenses | 13.20M | 16.14M | 18.63M | 17.46M | 16.75M |
| Depreciation & Amortization | 2.86M | 3.15M | 3.42M | 3.34M | 3.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.60M | 47.33M | 52.94M | 50.54M | 47.83M |
| Operating Income | -4.05M | -4.47M | -5.45M | -4.10M | -4.94M |
| Income Before Tax | -17.30M | -14.22M | -13.39M | -11.41M | -6.12M |
| Income Tax Expenses | 15.20K | 22.30K | 15.40K | 42.20K | -2.58M |
| Earnings from Continuing Operations | -17.31 | -14.24 | -13.40 | -11.45 | -3.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.31M | -14.24M | -13.40M | -11.45M | -3.54M |
| EBIT | -4.05M | -4.47M | -5.45M | -4.10M | -4.94M |
| EBITDA | -2.69M | -2.70M | -3.64M | -2.25M | -3.30M |
| EPS Basic | -0.21 | -0.17 | -0.17 | -0.15 | -0.06 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.13 |
| EPS Diluted | -0.21 | -0.17 | -0.17 | -0.15 | -0.06 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.13 |
| Average Basic Shares Outstanding | 347.76M | 334.57M | 311.59M | 287.92M | 268.96M |
| Average Diluted Shares Outstanding | 347.76M | 334.57M | 311.59M | 287.92M | 268.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |